Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.
2.

HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation.

Xu H, Zeng L, Peng H, Chen S, Jones J, Chew TL, Sadeghi MM, Kanwar YS, Danesh FR.

Am J Physiol Renal Physiol. 2006 Nov;291(5):F995-1004.

3.

Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability.

Sun H, Breslin JW, Zhu J, Yuan SY, Wu MH.

Microcirculation. 2006 Apr-May;13(3):237-47.

PMID:
16627366
4.

RhoA and Rho-kinase dependent and independent signals mediate TGF-beta-induced pulmonary endothelial cytoskeletal reorganization and permeability.

Clements RT, Minnear FL, Singer HA, Keller RS, Vincent PA.

Am J Physiol Lung Cell Mol Physiol. 2005 Feb;288(2):L294-306.

5.

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.

Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB.

Circ Res. 2002 Jul 26;91(2):143-50.

6.

Thrombin-induced phosphorylation of the regulatory light chain of myosin II in cultured bovine corneal endothelial cells.

Satpathy M, Gallagher P, Lizotte-Waniewski M, Srinivas SP.

Exp Eye Res. 2004 Oct;79(4):477-86.

PMID:
15381032
7.

Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux.

Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW.

J Biol Chem. 2005 Jun 10;280(23):22212-21.

8.

Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).

Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M.

Br J Pharmacol. 2001 Aug;133(7):1172-80.

9.

HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells.

Yokoyama K, Ishibashi T, Ohkawara H, Kimura J, Matsuoka I, Sakamoto T, Nagata K, Sugimoto K, Sakurada S, Maruyama Y.

Circulation. 2002 Feb 26;105(8):962-7.

10.

Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells.

Nishimoto-Hazuku A, Hirase T, Ide N, Ikeda Y, Node K.

J Cardiovasc Pharmacol. 2008 Mar;51(3):267-73. doi: 10.1097/FJC.0b013e3181624b44.

PMID:
18356691
11.

Antiangiogenic mechanisms of simvastatin in retinal endothelial cells.

Hata Y, Miura M, Asato R, Kita T, Oba K, Kawahara S, Arita R, Kohno R, Nakao S, Ishibashi T.

Graefes Arch Clin Exp Ophthalmol. 2010 May;248(5):667-73. doi: 10.1007/s00417-009-1282-4.

PMID:
20155363
12.

3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.

Wagner AH, Gebauer M, Güldenzoph B, Hecker M.

Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1784-9.

13.

Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1.

Peng H, Luo P, Li Y, Wang C, Liu X, Ye Z, Li C, Lou T.

PLoS One. 2013 Nov 14;8(11):e80009. doi: 10.1371/journal.pone.0080009.

14.

Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases.

van Nieuw Amerongen GP, van Delft S, Vermeer MA, Collard JG, van Hinsbergh VW.

Circ Res. 2000 Aug 18;87(4):335-40.

15.

How increased VEGF induces glomerular hyperpermeability: a potential signaling pathway of Rac1 activation.

Peng H, Wang C, Ye ZC, Chen YR, Zhang J, Chen ZJ, Yu XQ, Lou TQ.

Acta Diabetol. 2010 Dec;47 Suppl 1:57-63. doi: 10.1007/s00592-009-0121-8.

PMID:
19404567
16.

Impact of HMG CoA reductase inhibition on small GTPases in the heart.

Laufs U, Kilter H, Konkol C, Wassmann S, Böhm M, Nickenig G.

Cardiovasc Res. 2002 Mar;53(4):911-20.

PMID:
11922901
17.
18.

Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction.

van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW.

Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):E127-33.

19.

Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.

Danesh FR, Kanwar YS.

FASEB J. 2004 May;18(7):805-15. Review.

PMID:
15117885

Supplemental Content

Support Center